Advanced search
Publication Cover
HIV Clinical Trials Volume 7, 2006 - Issue 6
Submit an article Journal homepage
44
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Cost to Achieve an Undetectable Viral Load Using Recommended Antiretroviral Regimens

Rituparna P. BasuThe University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas
,
Richard M. GrimesThe University of Texas Health Science Center at Houston, School of Public Health, Houston, TexasCorrespondence[email protected]
&
Amgad F HelmySpokane Internal Medicine Residency ProgramSpokane, Washington, USA
Pages 309-318 | Published online: 06 Jan 2015

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Anita J. Brogan, Joseph Mrus, Andrew Hill, Anthony W. Sawyer & Erik Smets. (2010) Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States. HIV Clinical Trials 11:3, pages 133-144.
Read now
Andrew Hill, Lindsay Hemmett & Bernard Wilson. (2007) Analysis of Costs by CD4 Count Category for the Darunavir/r 600/100 mg bid and Control Protease Inhibitor Arms of the POWER 1 and 2 Trials. HIV Clinical Trials 8:5, pages 303-310.
Read now

Articles from other publishers (5)

Paola Codella, Silvia Coretti, Alessandra Fiore, Giuliano Rizzardini & Matteo Ruggeri. (2014) Cost-Effectiveness Studies in HIV Treatment with Lopinavir/Ritonavir: A Review. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 1:2, pages GRHTA.5000184.
Crossref
Vicente Soriano, Keikawus Arastéh, Horacio Migrone, Thomas Lutz, Milos Opravil, Jaime Andrade-Villanueva, Francisco Antunes, Giovanni Di Perri, Daniel Podzamczer, Steve Taylor, Pere Domingo, Holger Gellermann & Lothar de Rossi. (2010) Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. Antiviral Therapy 16:3, pages 339-348.
Crossref
Andrew M. Hill, Bonaventura Clotet, Margaret Johnson, Matthias Stoll, Nicholas Bellos & Erik Smets. (2012) Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients. PharmacoEconomics 28:S1, pages 69-81.
Crossref
Josephine Mauskopf, Lieven Annemans, Andrew M. Hill & Erik Smets. (2012) A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection. PharmacoEconomics 28:S1, pages 1-16.
Crossref
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, pages 910-928.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.